Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Refractory Hepatic Hydrothorax in Patients With Cirrhosis

被引:99
|
作者
Dhanasekaran, Renumathy [1 ]
West, Jonathan K. [1 ]
Gonzales, Patrick C. [1 ]
Subramanian, Ram [2 ]
Parekh, Samir [2 ]
Spivey, James R. [2 ]
Martin, Louis G. [1 ]
Kim, Hyun S. [1 ]
机构
[1] Emory Univ, Sch Med, Dept Radiol, Div Intervent Radiol & Image Guided Med, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA
来源
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2010年 / 105卷 / 03期
关键词
CHILD-PUGH; MANAGEMENT; SURVIVAL; ASCITES; TIPS; MELD;
D O I
10.1038/ajg.2009.634
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: We sought to study effectiveness, survival, and complications after transjugular intrahepatic portosystemic shunt (TIPS) in patients with cirrhosis and symptomatic refractory hepatic hydrothorax. METHODS: Consecutive patients who underwent TIPS between January 1992 and December 2008 for refractory hydrothorax were reviewed retrospectively. Clinical, laboratory, and procedural data were collected for all patients by retrospective chart review. Chi-square test was used to compare categorical variables and t-test to compare continuous variables. The Kaplan-Meier method was used for survival analysis. Survival curves were compared using the log-rank test. RESULTS: Seventy-three patients were included in the study, and their mean age at TIPS creation was 55.62 years (s.d. 11.65). The mean pre- and post-TIPS portosystemic gradients were 18.9 (s.d. 4.7) mm and 5.7 (s.d. 2.4) mm Hg (P<0.001), respectively. The rates of favorable clinical response within 1 month and at 6 months after TIPS were 79% (58/73) and 75% (30/40), respectively. Median of the study group was 517 days (95% CI 11-626). The short-term survival rates at 30, 60, and 90 days were 81, 78, and 72%, respectively. The long-term survival rates at 1, 3, and 5 years were 48, 26, and 15%, respectively. Multivariate analysis by Cox proportional hazards method showed that pre-TIPS model for end-stage liver disease (MELD) score (P=0.039, HR 1.9 (95% CI 1.0-3.7)) and clinical response (P=0.003, HR 2.5 (95 % CI 1.4-4.5)) were significantly and independently associated with overall survival. The 30-day mortality rate was 19 %. Pre-TIPS creatinine levels (P=0.024, HR 3.42 (95 % CI 1.2-9.9)) were significantly associated with 30-day mortality. CONCLUSIONS: TIPS can be successfully used to achieve symptomatic relief in patients with refractory hepatic hydrothorax. Better clinical response after TIPS and pre-TIPS MELD score less than 15 were associated with longer survival after TIPS.
引用
收藏
页码:635 / 641
页数:7
相关论文
共 50 条
  • [21] EFFICACY OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS FOR TREATMENT OF SYMPTOMATIC HEPATIC HYDROTHORAX
    CRENSHAW, WB
    GORDON, F
    PERRY, LJ
    MCENIFF, NJ
    JENKINS, RL
    CLOUSE, ME
    RADIOLOGY, 1995, 197 : 179 - 179
  • [22] Transjugular intrahepatic portosystemic shunt (TIPS) placement: A comparison of outcomes between patients with hepatic hydrothorax and patients with refractory ascites
    Young, S.
    Bermudez, J.
    Zhang, L.
    Rostambeigi, N.
    Golzarian, J.
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2019, 100 (05) : 303 - 308
  • [23] THERAPEUTIC OUTCOMES OF A TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT ON 5 PATIENTS OF INTRAHEPATIC ARTERIOPORTAL FISTULA PRESENTING REFRACTORY ASCITES OR HEPATIC HYDROTHORAX
    Hayama, Korenobu
    Kanazawa, Hidenori
    Tanabe, Tomohide
    Iwashita, Ai
    Harimoto, Hirotomo
    Kaneko, Keiko
    Atsukawa, Masanori
    Kawamoto, Chiaki
    Iwakiri, Katsuhiko
    GASTROENTEROLOGY, 2019, 156 (06) : S1351 - S1352
  • [24] TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT FOR SYMPTOMATIC PORTAL VEIN THROMBOSIS IN PATIENTS WITH CIRRHOSIS
    Han, Guohong
    Qi, Xingshun
    He, Chuangye
    Yin, Zhanxin
    Wang, Jianhong
    Xia, Jielai
    Niu, Jing
    Yang, Zhiping
    Bai, Ming
    Wu, Kaichun
    Fan, Daiming
    HEPATOLOGY, 2010, 52 (04) : 1078A - 1079A
  • [25] Transjugular intrahepatic portosystemic shunt vs. pleurodesis for treatment of symptomatic hepatic hydrothorax: A decision analysis
    Kiwi, ML
    Vaezi, MF
    Younossi, ZM
    Singer, ME
    GASTROENTEROLOGY, 1998, 114 (04) : A1276 - A1276
  • [26] Transjugular Intrahepatic Portosystemic Shunt for Medically Refractory Hepatic Hydrothorax: A Systematic Review and Meta-Analysis
    Al-Bawardy, Badr
    Ditah, Ivo C.
    Saberi, Behnam
    Gonzalez, Humberto C. Gonzalez
    Kamath, Patrick S.
    GASTROENTEROLOGY, 2014, 146 (05) : S932 - S933
  • [27] Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax
    Spencer, EB
    Cohen, DT
    Darcy, MD
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2002, 13 (04) : 385 - 390
  • [28] Treatment-refractory hydrothorax in primary biliary cirrhosis: successful treatment with a transjugular intrahepatic portosystemic stent shunt
    Nolte, W
    Figulla, HR
    Ringe, B
    Wiltfang, J
    Munke, H
    Hartmann, H
    Pausch, J
    Ramadori, G
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1997, 122 (42) : 1275 - 1280
  • [29] Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and post-transjugular intrahepatic portosystemic shunt complications in 2020
    Horhat, Adelina
    Bureau, Christophe
    Thabut, Dominique
    Rudler, Marika
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2021, 9 (02) : 203 - 208
  • [30] Efficacy and safety of transjugular intrahepatic portosystemic shunt in difficult-to-manage hydrothorax in cirrhosis
    Lindal, Ankur
    Mukund, Amar
    Kumar, Guresh
    Sarin, Shiv K.
    LIVER INTERNATIONAL, 2019, 39 (11) : 2164 - 2173